Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia

Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia

Low-dose cytarabine (LDAC) is a standard therapy for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. While high doses of cytarabine induce cytotoxicity, the precise mechanism of action of LDAC in AML remains elusive. In vitro studies have demonstrated LDAC-induced dif...

Full description

Bibliographic Details
Main Authors: Tomislav Smoljo, Barbara Tomic, Hrvoje Lalic, Vilma Dembitz, Josip Batinic, Antonio Bedalov, Dora Visnjic
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
cytarabine
differentiation
acute myeloid leukemia
bone marrow stromal cells
cell cycle
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1258151/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1258151/full

Similar Items